Genetic Information

Gene & Transcript Details

Gene
NRAS
Transcript
NM_002524.4 MANE Select
Total Exons
—
Reference Sequence
NC_000001.10
Alternative Transcripts
IDStatusDetails
NM_002524.4 Alternative 4454 nt | 255–824
NM_002524.5 MANE Select 4326 nt | 132–701
NM_002524.3 Alternative 4461 nt | 255–824
NM_002524.2 Alternative 1963 nt | 254–823

Variant Details

HGVS Notation
NM_002524.4:c.112-8A>G
Protein Change
?
Location
Exon 2 (Exon 2 of )
2
5'Exon Structure3'
Functional Consequence
Loss of Function
Alternate Identifiers
—

Clinical & Population Data

Population Frequency

gnomAD
Global Frequency
0.0256 in 100,000
Extremely Rare
ACMG Criteria Applied PM2
This variant is absent or extremely rare in population databases (PM2 criteria applies).

ClinVar

Open
Classification
Uncertain Significance (VUS)
4 publications
Clinical Statement

"This variant has been reported in ClinVar as Benign (2 clinical laboratories) and as Likely benign (4 clinical laboratories) and as Likely Benign (1 clinical laboratories) and as Uncertain significance (1 clinical laboratories) and as Likely Benign by ClinGen RASopathy Variant Curation Expert Panel expert panel."

COSMIC Somatic Evidence

Open
COSMIC ID
Recurrence
0 occurrences
PM1 Criteria
Not Applied
COSMIC Database Preview
COSMIC Preview
Accessing full COSMIC database details requires institutional login or subscription.

Functional Impact & Domains

Functional Domain

Hotspot Status
Not a hotspot
Domain Summary
This variant is not located in a mutational hotspot or critical domain.
Related Variants in This Domain
No evidence of other pathogenic variants at this position in gene NRAS.

Functional Studies & Therapeutic Relevance

Functional Summary

Error in OpenAI Consolidation. OncoKB: NRAS112-8A>GNRAS112-8A>GSomaticNCBI Gene:4893|Show additional gene information Variant OverviewNRAS, a GTPase, is mutated in a diverse range of cancers, most frequently in melanoma and thyroid cancer.The NRAS 112-8a>G mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown. JAX-CKB: No results found

Database Previews
OncoKB
OncoKB Preview
JAX-CKB
JAX-CKB Preview

Click on previews to view full database entries. External databases may require institutional access.

Computational Analysis

Pathogenicity Predictions

SpliceAI
Predictor Consensus
Mixed/VUS
PP3 Applied
No
REVEL Score
0.0
Threshold: ≥0.75 = PP3 applied

SpliceAI Scores

Window: ±500bp
Effect Type Score Position
- Acceptor Loss (AL) 0.02 -19 bp
- Donor Loss (DL) 0.0 199 bp
+ Acceptor Gain (AG) 0.0 242 bp
+ Donor Gain (DG) 0.0 393 bp
High impact (≥0.5) Medium impact (0.2-0.49) Low impact (<0.2)

VCEP Guidelines

Applied ACMG/AMP Criteria (VCEP Specific)

Filter Criteria:
PM2

PM2 (Unknown (Pre-LLM))

From pre-LLM assessment (LLM Failed)

BP4

BP4 (Unknown (Pre-LLM))

From pre-LLM assessment (LLM Failed)